In this episode, Ji Liu, primary analyst for Bausch Health, discusses a number of investor questions after Bausch announced its intention to spin off its eye health business unit, specifically regarding its capital structure, key business str

Regeneron Pharmaceuticals: Steady Growth vs. Heavy Product Concentration

Aug 5th, 2020 8m 2s

S&P Global Ratings' senior pharma analyst, Ji Liu, discusses the puts and takes for our new Regeneron Pharmaceuticals ratings.

Episode 34: More Color on PPD’s Rating After IPO

Feb 11th, 2020 6m 48s

In this episode of S&P Pharma Dose, senior healthcare analyst Ji Liu discusses his view on Pharmaceutical Product Development LLC (PPD) after its recent IPO on Feb. 5, 2020.

Episode 33: Pharmacy Benefit Manager Industry In 2020: Less Regulatory Overhang, Expect More Consolidations

Jan 21st, 2020 10m 25s

In this episode of S&P Pharma Dose, Ji Liu, Deep Banerjee and Andy Sookram discuss the annual PBM outlook report along with their view on high-profile issuers UnitedHealth, Cigna, CVS and Rite Aid.

Episode 32: Pfizer Finds Home For Upjohn, Though Lessened Diversity Results In Lower Rating

Aug 1st, 2019 8m 45s

The S&P Pharma Guy, Arthur Wong, shares S&P Global’s thoughts on Pfizer Inc.’s announcement it was spinning off Upjohn, home to legacy products Lipitor, Viagra, and Lyrica. Pfizer remains a pharma giant and leading player in the industry. Howev

Episode 31: Thoughts On Pharma’s Washington Grilling

Mar 7th, 2019 12m 8s

S&P Global’s pharmaceutical themed podcast show returns with some quick thoughts on the pharma industry’s testimony at a congressional hearing on Capitol Hill. A comprehensive list of challenges/criticisms of the industry, but where were the su

Episode 30: Rebates And Pharma Supply Chain

Aug 3rd, 2018 10m 6s

Healthcare analysts Tulip Lim and Ji Liu drop in on the S&P Pharma Guy, Arthur Wong, to talk how HHS's proposal to ban rebating from the Medicare market. What's the impact on the ratings of the pharma supply chain players?

Episode 29: Just When You Thought It Was Safe to Go Back In the Water - Amazon Buys PillPack

Jul 11th, 2018 17m 26s

Managing Director, Bob Schulz from S&P Global's retail team and Director, Tulip Lim, of the healthcare team drop in on the show to share thoughts on Amazon's recent no-longer-a-rumor move into the pharmacy space. What does it mean for the pharm

Episode 28: President Trump's American Patient First Speech - Placebo?

May 18th, 2018 10m 38s

The S&P Pharma Guy, Arthur Wong, shares S&P Global's initial thoughts on President Trump's recent speech on lowering drug prices. The speech questioned the validity of drug rebates and criticized foreign countries for paying too little for drug

Episode 27: Bezos, Buffett, and Dimon - Welcome to the Healthcare Party

Feb 5th, 2018 13m 56s

A surprise announcement by Amazon.com Inc., Berkshire Hathaway Inc., and JPMorgan Chase & Co. that they are jointly forming a new company to tackle health costs for their employees has caused quite a stir. S&P pharma analyst, Arthur Wong, share

Episode 26: Generic Drug Pricing - When Does the Pain Stop?

Feb 2nd, 2018 17m 38s

The S&P Pharma Guy, Arthur Wong, shares why generic drug pricing in the U.S., which has been under increasing pressure, should begin to stabilize in 2018. However, the U.S. generic drug environment will likely remain challenging over the near t

Episode 25: Four Things We Are Watching For On Teva

Dec 7th, 2017 18m 3s

The S&P Pharma Guy, Arthur Wong details four things S&P is watching for on Teva over the next three quarters that would help determine whether the ratings stay investment grade.

Episode 24: Et Tu Amazon? Amazon and Impact on Pharma Pricing

Nov 15th, 2017 9m 16s

S&P Global Ratings analyst Arthur Wong takes an early look as to what a possible entry of Amazon.com Inc. into the pharma ecosystem may mean to drug pricing for generic and branded pharma. Warning: More questions than answers at this point.

Episode 23: CVS Health Possibly Seeks to Buy Aetna - Surprised? You Shouldn't Be

Nov 3rd, 2017 7m 56s

S&P Global Ratings analyst Arthur Wong shares why a potential CVS Health/Aetna is not that all surprising, and that it will mean more pricing pressure on the pharmaceutical industry as well as drive further consolidation in the pharmaceutical c

Episode 22: Reflections - Mylan NV Earnings 2Q17

Sep 6th, 2017 11m 27s

Guest analyst, Kim Logan, drops in to share her reflections on generic giant Mylan NV's second quarter performance and shares her thoughts on the company maintaining investment grade ratings.

Episode 21: Endo Intl Downgrade to 'B' - Litigation, Generics, and Opioids

Aug 17th, 2017 13m 48s

S&P Global Ratings analyst Arthur Wong discusses the recent downgrade of Endo International, which took another significant charge for its mesh litigation settlement, while dealing with ongoing pressures in the generic and opioid markets.

Episode 20: Rite Aid Corp. - What's Next For the Company?

Aug 16th, 2017 8m 31s

S&P Global Ratings retail analyst Andy Sookram swings by the show to discuss the ratings and prospects of major U.S. pharmacy player, Rite Aid, now that its merger with rival Walgreens Boots Alliance Inc. has been canceled, and is instead selli

Episode 19: Reflections - Eli Lilly Earnings 2Q17

Jul 26th, 2017 10m 32s

S&P Global Ratings credit analyst Arthur Wong shares his thoughts on Eli Lilly's recent earnings call, including thoughts on top drug prospect, the rheumatoid arthritis treatment, baricitinib, continued sales and margin growth, pipeline challen

Episode 16: Four Takeaways - Amgen Inc.

Jun 15th, 2017 12m 20s

S&P Global Ratings credit analyst Arthur Wong discusses the ratings and outlook on Amgen Inc., its challenge in replacing the declining sales of stalwart products such as Epogen/Aranesp, Neupogen/Neulasta, and Enbrel, and its capacity for debt

Episode 17: Pharma Outlook in 7 Minutes

Jun 15th, 2017 9m 8s

S&P Global Ratings credit analyst Arthur Wong attempts to share S&P's current thoughts on the ratings outlook for pharmaceuticals in seven minutes or less, given looming U.S. corporate tax reform, continued industry M&A, and challenges faced by

Episode 15: Pharma Chat - CRO Consolidation

Jun 15th, 2017 17m 2s

S&P Global Ratings credit analysts Matt Todd and Arthur Wong chat about various recent topics in the industry, including consolidation in the contract research organization space and the potential return of speculative inventory buying.

Episode 14: PBMs Still Have a Role? Focus on Express Scripts

Apr 5th, 2017 15m 30s

S&P Global Ratings credit analyst Shannan Murphy drops in on the show to discuss the role of pharmacy benefit managers (PBMs) in this changing health care market, with a focus on a major independent PBM, Express Scripts Holding Co.

Episode 13: Four Takeaways - Merck & Co.

Apr 5th, 2017 9m 28s

S&P Global Ratings credit analyst Arthur Wong discusses the ratings and outlook on Merck & Co. Inc., prospects of Keytruda, and what capacity the company has for acquisitions at the current ratings.

Episode 12: Pharma Chat - It's All in the Transparency

Feb 2nd, 2017 9m 12s

Analysts Arthur Wong and Adam Dibe discuss pharma trying to improve their public image, pharma pricing and transparency, Merck's disclosing their gross and net pricing, and Johnson & Johnson's acquisition of Actelion.

Episode 11: Four Takeaways - Eli Lilly

Jan 13th, 2017 10m 21s

Analyst Arthur Wong discusses the ratings and outlook on Eli Lilly, in the wake of the company's upbeat earnings guidance despite the recent loss of its high profile drug prospect, the Alzheimer's treatment, solanezumab.